Dose-dense first-line chemotherapy in advanced ovarian cancer: How to select the patients?

被引：0
|
作者：
Tjulandina, Alexandra
Stenina, Marina
Pokataev, Ilya
Fedyanin, Mikhail
Tryakin, Alexey
Tjulandin, Sergei
机构：
[1] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[2] Russian Acad Med Sci, NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[3] NN Blokhin Canc Res Ctr, Russian Oncol Res Ctr, Moscow, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16509
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer
    Zhang, Li
    Zhou, Qi
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 837 : 64 - 71
  • [2] Dose-dense chemotherapy in advanced ovarian cancer
    Bookman, Michael A.
    LANCET, 2009, 374 (9698): : 1303 - 1305
  • [3] Efficacy of dose-dense chemotherapy as first-line treatment of advanced ovarian cancer patients after non-optimal debulking.
    Rumyantsev, Alexey
    Tyulyandina, Alexandra
    Pokataev, Ilya
    Morkhov, Konstantin
    Nechuskina, Valentina Mikhailovna
    Tjulandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer
    Fleming, Nicole D.
    Coleman, Robert L.
    Tung, Celestine
    Westin, Shannon N.
    Hu, Wei
    Sun, Yunjie
    Bhosale, Priya
    Munsell, Mark F.
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 41 - 46
  • [5] Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer
    Fleming, N. D.
    Coleman, R. L.
    Tung, C. S.
    Munsell, M. F.
    Sood, A. K.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 79 - 79
  • [6] EFFICACY AND SAFETY OF TC DOSE-DENSE CHEMOTHERAPY IN FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER; A RETROSPECTIVE COHORT STUDY IN THE SINGLE INSTITUTION
    Vrdoljak, J.
    Boban, T.
    Mise, B. Petric
    Jelavic, T. Boraska
    Bajic, Z.
    Tomic, S.
    Vrdoljak, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 866 - 866
  • [7] DOSE-DENSE PACLITAXEL AND CARBOPLATIN PLUS BEVACIZUMAB IS AN EFFECTIVE AND A TOLERABLE FIRST-LINE REGIMEN FOR ADVANCED OVARIAN CANCER
    Komazaki, H.
    Takahashi, K.
    Tanabe, H.
    Shoburu, Y.
    Izumi, A.
    Kamii, M.
    Tsuda, A.
    Saito, M.
    Yamada, K.
    Takano, H.
    Niimi, S.
    Okamoto, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A169 - A170
  • [8] First-line chemotherapy in advanced ovarian cancer
    Colombo, N
    Parma, G
    Caspani, G
    Donesana, P
    Marinetti, E
    Mangioni, C
    TUMORI JOURNAL, 1999, 85 (03): : S23 - S26
  • [9] Weekly dose-dense chemotherapy for ovarian cancer
    Tanday, Sanjay
    LANCET ONCOLOGY, 2016, 17 (04): : E138 - E138
  • [10] Dose-dense paclitaxel for advanced ovarian cancer
    Bellati, Filippo
    Calcagno, Marco
    Panici, Pierluigi Benedetti
    LANCET, 2010, 375 (9711): : 280 - 280
12345